Abstract 122P
Background
The benefit of immune checkpoint blockade (ICB) in cancer therapy is limited to select patient subsets. ICB resistance factors include accumulation of immunosuppressive adenosine. Pharmacological inhibition of adenosine generation and signaling is under clinical investigation. Here we report a novel mechanism where adenosine suppresses anti-cancer immunity via intracellular transport.
Methods
Intratumoral adenosine levels in human tumors was quantified via quantitative mass spectrometry imaging (QMSI). T cell uptake of adenosine was assessed through radiolabeled uptake. In vitro T cell function was assessed by flow cytometry, metabolic flux analysis and liquid chromatography-mass spectrometry. Functional consequences of adenosine on T cell function were assessed in vitro via activation of memory and tumor-infiltrating T cells (TILs) and in vivo by assessing tumor growth in syngeneic mouse tumors and pharmacologic inhibition in humanized mice.
Results
QMSI revealed the accumulation of adenosine concentrations up to 300 μM in human tumors. Activated human T cells increased expression of equilibrative nucleoside transporter 1 (ENT1), resulting in adenosine uptake, inhibition of pyrimidine nucleotide production and suppressed proliferation. This was associated with diminished effector function and mitochondrial respiration. ENT1 deletion improved tumor control in syngeneic models including KPC, a poorly immunogenic pancreatic cancer model, increasing CD8+ TIL proliferation and cytokine production. ENT1-KO mice rejected MC38 tumor growth and remained resistant upon rechallenge. To target ENT1 therapeutically, we designed EOS-984, a novel and potent ENT1 antagonist currently under evaluation in advanced solid tumor patients. EOS-984 blocked intracellular adenosine transport, rescuing proliferation and function of T cells stimulated in the presence of adenosine in vitro. In a humanized mouse model of anti-PD-1-resistant TNBC (MDA-MB-231), EOS-984 controlled tumor growth synergistically with nivolumab.
Conclusions
In conclusion, intracellular adenosine metabolism is a novel mechanism of T cell immunosuppression, amenable to ENT1 inhibition to enhance anti-cancer immune responses.
Legal entity responsible for the study
iTeos Therapeutics.
Funding
iTeos Therapeutics.
Disclosure
E. Houthuys, T. Sanders, M. Brouwer, A. Hermant, L. Chaible, J. Deglasse, A. Pabois, W. Cathou, A. Smets, M. Deligny, J. Marchante, Q. Dubray, M. Letellier, C. Martinoli, R. Marillier, O. De Henau, Y. McGrath: Financial Interests, Personal, Full or part-time Employment: iTeos Therapeutics; Financial Interests, Personal, Stocks/Shares: iTeos Therapeutics. M. Vander Heiden: Financial Interests, Personal, Advisory Board: iTeos Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract